HNGE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Hinge Health Inc (HNGE) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company demonstrates strong financial growth and positive revenue trends, the current technical indicators and price action suggest bearish momentum. Additionally, the lack of significant positive trading signals and the recent insider selling activity further reduce the appeal of the stock as a buy right now. Holding off for a better entry point or further confirmation of bullish momentum is advisable.
The technical indicators suggest a bearish trend. The MACD is negatively expanding, RSI is neutral but leaning towards oversold territory, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 35.997), with resistance levels at R1: 40.597 and R2: 42.017. Overall, the stock is in a downtrend.
Strong financial performance in Q4 2025, with revenue up 45.6% YoY and net income up 18.36% YoY.
Analysts maintain positive ratings, with price targets ranging from $45 to $59, indicating potential upside.
The company is expanding into adjacent markets like women's health and fall prevention, which could drive future growth.
Recent insider selling by Director Gabriel M.I. Mecklenburg, who sold 50,000 shares and reduced direct holdings to zero.
The stock has declined 15% year-to-date, indicating weak momentum.
Technical indicators and price action suggest bearish sentiment in the short term.
In Q4 2025, Hinge Health reported a 45.6% YoY revenue increase to $171 million, net income growth of 18.36% YoY to $32.1 million, and EPS growth of 14.29% YoY to $0.4. Gross margin also improved to 84.36%, up 2.94% YoY, showcasing strong financial health and operational efficiency.
Analysts maintain an overall positive outlook with Outperform and Buy ratings. Recent price target adjustments reflect a range of $45 to $59, with a focus on the company's growth potential in new markets and its strong financial performance. However, some analysts have lowered targets due to market volatility and conservative guidance.
